Johnson & Johnson's ICOTYDE Shows Significant Improvement in Psoriasis with New Data
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 1 day ago
0mins
Should l Buy JNJ?
Source: NASDAQ.COM
- Clinical Trial Results: Johnson & Johnson's ICOTYDE achieved up to 49% complete skin clearance in the ICONIC-ADVANCE 1 and 2 studies at 52 weeks, significantly improving from 41% at 24 weeks, indicating its effectiveness in treating moderate-to-severe psoriasis.
- Patient Transition Impact: Patients switching from placebo to ICOTYDE at Week 16 achieved clearance rates of 50% and 43% by Week 52, demonstrating the drug's rapid efficacy and enhancing its clinical application potential.
- Sustained Efficacy in Adolescents: In the ICONIC-LEAD study, nearly 60% of adolescent patients achieved complete skin clearance at Week 52, with 86% reaching PASI 90 response, indicating ICOTYDE's durable efficacy and safety across different age groups.
- Safety Profile Analysis: The safety profile of ICOTYDE remained consistent with earlier data, with no new safety signals identified, and overall adverse event and infection rates lower than those observed with the comparator drug deucravacitinib, further solidifying its position as a safe and effective oral therapy.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy JNJ?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on JNJ
Wall Street analysts forecast JNJ stock price to fall
20 Analyst Rating
13 Buy
7 Hold
0 Sell
Moderate Buy
Current: 240.450
Low
190.00
Averages
218.50
High
240.00
Current: 240.450
Low
190.00
Averages
218.50
High
240.00
About JNJ
Johnson & Johnson and its subsidiaries are engaged in the research and development, manufacture, and sale of a range of products in the healthcare field. The Company’s segments include Innovative Medicine and MedTech. The Innovative Medicine segment is focused on various therapeutic areas, including immunology, infectious diseases, neuroscience, oncology, pulmonary hypertension, cardiovascular and metabolism. Its products include REMICADE (infliximab), SIMPONI (golimumab), SIMPONI ARIA (golimumab), STELARA (ustekinumab), TREMFYA (guselkumab), EDURANT (rilpivirine), and INVEGA SUSTENNA/XEPLION (paliperidone palmitate). The MedTech segment includes a portfolio of products used in cardiovascular, orthopedics, surgery, and vision categories. The Cardiovascular portfolio includes electrophysiology products to treat heart rhythm disorders and circulatory restoration products (Shockwave) for the treatment of calcified coronary artery disease (CAD) and peripheral artery disease (PAD).
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Royalty Pharma Partners with Johnson & Johnson in $500M R&D Deal
- Collaborative R&D Agreement: Royalty Pharma has entered into a $500 million R&D funding agreement with Johnson & Johnson, aimed at supporting the development of a new autoimmune treatment between 2026 and 2027, highlighting the potential for deep collaboration in the biopharmaceutical sector.
- New Therapy Development: The partnership will focus on JNJ-4804, a novel co-antibody therapy that blocks both IL-23 and tumor necrosis factor (TNF) pathways, delivering synergistic effects on the pathogenesis of chronic immune-mediated diseases, potentially offering more effective treatment options for patients.
- Market Impact: This collaboration not only accelerates the clinical development of the new therapy but also enhances the competitive positioning of both Royalty Pharma and Johnson & Johnson in the autoimmune disease treatment market, further solidifying their leadership in the biopharmaceutical industry.
- Strategic Significance: Through this partnership, Royalty Pharma demonstrates its commitment to innovative drug development while adding new treatment options to Johnson & Johnson's product line, indicating ongoing investment and growth potential in the biopharmaceutical field.
See More
Royalty Pharma and Johnson & Johnson Sign $500 Million Co-Funding Agreement
- Co-Funding Agreement: Royalty Pharma's $500 million co-funding agreement with Johnson & Johnson aims to advance the development of JNJ-4804 in 2026 and 2027, highlighting the company's strategic investment intentions in the biopharmaceutical sector.
- Innovative Drug Development: JNJ-4804 is a co-antibody therapy designed to block complementary interleukin-23 and tumor necrosis factor pathways, which, if successful, will provide new treatment options for autoimmune disease patients and further solidify Royalty Pharma's position in biopharmaceutical innovation.
- Portfolio Expansion: Royalty Pharma's current portfolio includes royalties on over 35 commercial products and 19 development-stage candidates, and this collaboration is expected to enhance its influence and competitiveness in the biopharmaceutical industry.
- Positive Market Reaction: In pre-market trading on Nasdaq, Royalty Pharma shares rose 1.4% to $47.00, reflecting market optimism regarding the co-funding agreement and its potential financial benefits.
See More
Royalty Pharma Enters Agreement to Propel Development of JNJ-4804 for Autoimmune Disorders
Agreement Overview: Royalty Pharma has entered into an agreement to advance the development of JNJ-4804, a treatment for autoimmune diseases.
Focus on Autoimmune Diseases: The collaboration aims to enhance the research and development efforts for JNJ-4804, targeting various autoimmune conditions.
See More
Royalty Pharma Reveals $500 Million R&D Co-Funding Partnership with Johnson & Johnson for 2026-2027
Funding Announcement: Royalty Pharma has announced a $500 million R&D co-funding agreement with Johnson & Johnson for the years 2026-2027.
Collaboration Details: The agreement aims to support the development of innovative therapies and enhance research capabilities between the two companies.
See More
The Iran Conflict May Persist: Current Investment Opportunities for Success.
- Current Market Status: The Nasdaq is currently in a correction, having dropped over 10% from its recent highs.
- Bear Market Concerns: There are increasing fears that the Nasdaq may soon enter a bear market, defined as a decline of 20%.
- Wall Street Perspective: Despite the downturn, there is a common belief on Wall Street that opportunities for profit exist in other sectors.
- Market Sentiment: The overall sentiment reflects anxiety about the tech-heavy index's performance amidst potential further declines.
See More
Deutsche Bank Sees AtaiBeckley as a Leader in Psychedelic Renaissance
- Positive Market Outlook: Deutsche Bank initiated coverage on AtaiBeckley with a buy rating and a $12 price target, indicating over a 250% upside from Friday's close, reflecting strong market confidence in its position within the psychedelic drug sector.
- Drug Development Potential: AtaiBeckley is developing two key drugs for treatment-resistant depression, BPL-003 and VLS-01, with potential U.S. sales peaking at $4 billion and $2 billion respectively, highlighting significant market opportunities for its product pipeline.
- Increased Industry Recognition: As psychedelic therapies gain popularity in mental health treatment, Deutsche Bank's analyst noted that AtaiBeckley has emerged as a bona fide drug developer, attracting interest from investors typically focused on conventional therapeutics, underscoring its leadership in this nascent market.
- FDA Regulatory Changes: Hoang mentioned that the FDA's skepticism towards psychedelic therapies has eased, with expectations that upon FDA approval, these drugs will undergo federal rescheduling within 90 days, further enhancing market acceptance and investor confidence.
See More
Royalty Pharma Partners with Johnson & Johnson in $500M R&D Deal
- Collaborative R&D Agreement: Royalty Pharma has entered into a $500 million R&D funding agreement with Johnson & Johnson, aimed at supporting the development of a new autoimmune treatment between 2026 and 2027, highlighting the potential for deep collaboration in the biopharmaceutical sector.
- New Therapy Development: The partnership will focus on JNJ-4804, a novel co-antibody therapy that blocks both IL-23 and tumor necrosis factor (TNF) pathways, delivering synergistic effects on the pathogenesis of chronic immune-mediated diseases, potentially offering more effective treatment options for patients.
- Market Impact: This collaboration not only accelerates the clinical development of the new therapy but also enhances the competitive positioning of both Royalty Pharma and Johnson & Johnson in the autoimmune disease treatment market, further solidifying their leadership in the biopharmaceutical industry.
- Strategic Significance: Through this partnership, Royalty Pharma demonstrates its commitment to innovative drug development while adding new treatment options to Johnson & Johnson's product line, indicating ongoing investment and growth potential in the biopharmaceutical field.
See More
Royalty Pharma and Johnson & Johnson Sign $500 Million Co-Funding Agreement
- Co-Funding Agreement: Royalty Pharma's $500 million co-funding agreement with Johnson & Johnson aims to advance the development of JNJ-4804 in 2026 and 2027, highlighting the company's strategic investment intentions in the biopharmaceutical sector.
- Innovative Drug Development: JNJ-4804 is a co-antibody therapy designed to block complementary interleukin-23 and tumor necrosis factor pathways, which, if successful, will provide new treatment options for autoimmune disease patients and further solidify Royalty Pharma's position in biopharmaceutical innovation.
- Portfolio Expansion: Royalty Pharma's current portfolio includes royalties on over 35 commercial products and 19 development-stage candidates, and this collaboration is expected to enhance its influence and competitiveness in the biopharmaceutical industry.
- Positive Market Reaction: In pre-market trading on Nasdaq, Royalty Pharma shares rose 1.4% to $47.00, reflecting market optimism regarding the co-funding agreement and its potential financial benefits.
See More
Royalty Pharma Enters Agreement to Propel Development of JNJ-4804 for Autoimmune Disorders
Agreement Overview: Royalty Pharma has entered into an agreement to advance the development of JNJ-4804, a treatment for autoimmune diseases.
Focus on Autoimmune Diseases: The collaboration aims to enhance the research and development efforts for JNJ-4804, targeting various autoimmune conditions.
See More
Royalty Pharma Reveals $500 Million R&D Co-Funding Partnership with Johnson & Johnson for 2026-2027
Funding Announcement: Royalty Pharma has announced a $500 million R&D co-funding agreement with Johnson & Johnson for the years 2026-2027.
Collaboration Details: The agreement aims to support the development of innovative therapies and enhance research capabilities between the two companies.
See More
The Iran Conflict May Persist: Current Investment Opportunities for Success.
- Current Market Status: The Nasdaq is currently in a correction, having dropped over 10% from its recent highs.
- Bear Market Concerns: There are increasing fears that the Nasdaq may soon enter a bear market, defined as a decline of 20%.
- Wall Street Perspective: Despite the downturn, there is a common belief on Wall Street that opportunities for profit exist in other sectors.
- Market Sentiment: The overall sentiment reflects anxiety about the tech-heavy index's performance amidst potential further declines.
See More
Deutsche Bank Sees AtaiBeckley as a Leader in Psychedelic Renaissance
- Positive Market Outlook: Deutsche Bank initiated coverage on AtaiBeckley with a buy rating and a $12 price target, indicating over a 250% upside from Friday's close, reflecting strong market confidence in its position within the psychedelic drug sector.
- Drug Development Potential: AtaiBeckley is developing two key drugs for treatment-resistant depression, BPL-003 and VLS-01, with potential U.S. sales peaking at $4 billion and $2 billion respectively, highlighting significant market opportunities for its product pipeline.
- Increased Industry Recognition: As psychedelic therapies gain popularity in mental health treatment, Deutsche Bank's analyst noted that AtaiBeckley has emerged as a bona fide drug developer, attracting interest from investors typically focused on conventional therapeutics, underscoring its leadership in this nascent market.
- FDA Regulatory Changes: Hoang mentioned that the FDA's skepticism towards psychedelic therapies has eased, with expectations that upon FDA approval, these drugs will undergo federal rescheduling within 90 days, further enhancing market acceptance and investor confidence.
See More
